ECT may be a successful treatment for some cases of tardive dyskinesia. In this review, the authors accumulate all the recent evidence for the efficacy of ECT in treating tardive dyskinesia and make recommendations following data analysis.
Recognition of sex differences can promote a more personalized patient-centered care approach to ensure goals of therapy are achieved among patients prescribed antipsychotics. Read on to find out more.
In this report, the authors describe the successful management of tardive dyskinesia with quetiapine in a man with schizoaffective disorder and comorbid diabetes with renal and neurologic complications as well as hypothyroidism and hypertension.
Management of resistant depression is challenging, as many patients have tried multiple medications and psychotherapy with no success. This report describes a case of resistant depression successfully treated with an intranasal form of ketamine.
Neuroleptic malignant syndrome (NMS) is often associated with use of typical antipsychotics, but antiepileptics have also been implicated. This report describes the case of an elderly man with schizophrenia who experienced NMS with valproate.
Psychiatric patients are susceptible to cardiovascular disease (CVD), but this risk is poorly understood. This study compared CVD risk in psychiatric patients taking weight gain-inducing drugs with that in the general population.
How soon is too soon to look for metabolic syndrome in your patients with schizophrenia? This randomized open-label trial investigates 7 risk factors of 5 atypical and 2 typical antipsychotics to make recommendations for monitoring metabolic measurements.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”